Wednesday, July 8, 2026

biotech · Relapsed/Refractory Large B Cell Lymphoma · Relapsed/Refractory Multiple Myeloma · ALLO

Allogene Therapeutics

NovaPharmaNews editorial coverage mentioning Allogene Therapeutics — regulatory, clinical, and market analysis.

South San Francisco, USA HQ
2017 Founded
208 Employees
Public company Type
ALLO · NYSE Ticker
Company details
Status
Public
HQ
South San Francisco, USA
Founded
2017
Employees
208
Programs
8
Drugs
2
Patents
16
Intelligence · Coverage

News & analysis

NovaPharmaNews articles mentioning Allogene Therapeutics — regulatory, clinical, and market coverage.

NovaPharmaNews editorial coverage mentioning Allogene Therapeutics — regulatory, clinical, and market analysis.

No coverage yet

We have not published news or analysis mentioning Allogene Therapeutics yet.

Back to company overview →